Hestia Insight Inc. (HSTA)
| Previous close | 0.4790 |
| Open | 0.1520 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4790 - 0.4790 |
| 52-week range | 0.0300 - 0.8240 |
| Volume | |
| Avg. volume | 19 |
| Market cap | 27.346M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6950 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireHestia Insight Inc. Announces Upcoming Launch of AI-Powered IR Website Platform to Assist Start-Ups, Small and Medium Sized Companies
NEW YORK, NY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that in September 2023, its wholly owned subsidiary, Hestia Investments Inc. (“Hestia Inve
- GlobeNewswire
Hestia Insight Inc. Signs Letter of Intent With Leading Wound Care Company
NEW YORK, NY, May 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced that it has entered into a Letter of Intent with RecentCare Biomedical, Inc., Taipei, Taiwan, (“RecentCare Biomedical”), a leading
- GlobeNewswire
Hestia Insight Inc. Signs Letter of Intent With Major Asian-Pacific Health Care Products Distributor
NEW YORK, NY, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced that it has entered into a Letter of Intent with Prisma Biotech Corporation, Taipei, Taiwan, (“Prisma Biotech”), beginning the pot
